Looking back at cytomegalovirus after stem cell transplant in children in Italy
Reviews past records of cytomegalovirus reactivation and its costs in children after stem cell transplant.
Key facts
- Who runs it
- MSD Italia S.r.l.
- Where
- Italy5 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- Recruiting
- People taking part
- 230 people, planned
- Started
- 9 May 2025
- Planned end
- 15 Jul 2026
- Type of study
- Observational
- Record updated
- 6 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children who had an allogeneic stem cell transplant (cells from a donor) in Italy. It reviews past records about cytomegalovirus (CMV) coming back after transplant.
- Age
- From birth to less than 18 years of age at the time of the transplant.
- Sex
- All sexes can join.
- Disease stage
- Children who received an allogeneic hematopoietic stem cell transplant between January 2018 and June 2020.
- Earlier treatment
- Must have had an allogeneic HSCT between January 2018 and June 2020. Cannot join if Letermovir was ever used.
Main reasons for not taking part
- Letermovir use at any time
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients from birth to less than 18 years of age (at the moment of the allogeneic HSCT)
- Patients who received allogeneic HSCT between January 2018 and June 2020
- Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable
Who cannot take part
- Letermovir use at any time
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 18 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- CMV PED Study - A Retrospective Observational Study To Understand The Clinical And Economic Burden Associated With Cytomegalovirus Reactivation and Related Health Outcomes In Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation In Italy
- Plain-language title
- Looking back at cytomegalovirus after stem cell transplant in children in ItalyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06916195, who can take part
- Record updated
- 6 April 2026